Idiopathic Thrombocytopenic Purpura (ITP) Clinical Trials
Novartis CVAY736Q1US01
A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated With At least One Treatment (VAY2EXPLORE)